Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed […]
SAB Biotherapeutics Announces Executive Leadership Change
SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage […]
TSX News -
Guardian Capital Group Limited to Acquire Sterling Capital Management LLC
TORONTO, Feb. 02, 2024 (GLOBE NEWSWIRE) — Guardian Capital Group Limited (Guardian) (TSX:GCG) (TSX:GCG.A) announced today that it has reached […]
Altair To Host Investor Day on Wednesday, March 20, 2024
TROY, Mich., Feb. 02, 2024 (GLOBE NEWSWIRE) — Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence, today […]
Shenandoah Telecommunications Company to Hold its Fourth Quarter and Full Year 2023 Earnings Call at 8:30 a.m. on Wednesday, February 21, 2024
EDINBURG, Va., Feb. 02, 2024 (GLOBE NEWSWIRE) — Shenandoah Telecommunications Company (Shentel) (NASDAQ:SHEN) will release its fourth quarter and full […]
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) — Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa […]
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
– Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with […]
Plug Signs BEDP Contract for a 500MW Electrolyzer in Europe
LATHAM, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions […]
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular […]
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) — Sio Gene Therapies, Inc. (“Sio”) today announced that it expects to file […]
